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Abstract: DMPC-10A (ALWKKLLKK-Cha-NH2) is a 10-mer peptide derivative from the N-terminal
domain of Dermaseptin-PC which has shown broad-spectrum antimicrobial activity as well
as a considerable hemolytic effect. In order to reduce hemolytic activity and improve stability to
endogenous enzymes, a D-amino acid enantiomer (DMPC-10B) was designed by substituting all
L-Lys and L-Leu with their respective D-form amino acid residues, while the Ala1 and Trp3 remained
unchanged. The D-amino acid enantiomer exhibited similar antimicrobial potency to the parent peptide
but exerted lower cytotoxicity and hemolytic activity. Meanwhile, DMPC-10B exhibited remarkable
resistance to hydrolysis by trypsin and chymotrypsin. In addition to these advantages, DMPC-10B
exhibited an outstanding antibacterial effect against Methicillin-resistant Staphylococcus aureus (MRSA)
and Klebsiella pneumoniae using the Galleria mellonella larva model and displayed synergistic activities
with gentamicin against carbapenem-resistant K. pneumoniae strains. This indicates that DMPC-10B
would be a promising alternative for treating antibiotic-resistant pathogens.
Keywords: antimicrobial peptide; D-amino acid; protease stability; Galleria mellonella larva model
1. Introduction
Nowadays, infectious diseases are an increasingly serious phenomenon, mainly due to an increase
in antibiotic-resistant pathogens. Ten million people worldwide are estimated to die from infections by
drug-resistant bacteria by 2050 [1]. Antimicrobial peptides (AMPs) have received attention for their
broad-spectrum antimicrobial activity and low toxicity against mammalian cells, and they are less
likely to produce drug resistance [2–5] as they can target phospholipids and disrupt the cell membrane
of pathogens. However, some disadvantages of naturally occurring peptides, such as poor chemical
and physical stability, a tendency toward aggregation, and a short half-life and fast elimination, limit
their potential for clinical applications [6].
Dermaseptins are a class of cationic AMPs that were discovered from the skin of Phyllomedusa
frogs, usually consisting of 28–34 amino acids. They can form an amphipathic α-helix in amphiphilic
environments, which makes them bind easily to bacterial lipid bilayers [7,8]. Dermaseptins contain
a conserved Trp residue in position three and a unique internal motif, -AAA/GKAAL/G/NA-, and exert
broad-spectrum antimicrobial activity against a range of ESKAPE pathogens [7,8]. It has been suggested
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that the N-terminal domain of dermaseptin demonstrates selectivity during the interaction with
the bacterial cell membrane, while the C-terminal helix mainly exhibits nonspecific membrane lytic
activity [9,10]. Previous research of N-terminal peptide fragments of dermaseptins has shown that 16- to
19-mer truncated peptide retains similar antimicrobial potency, while shorter sequences (less than 13 amino
acid residues) lose massive antimicrobial activity [11,12]. In our previous study, we designed an optimized
decapeptide derived from a dermaseptin N-terminal derivative, DMPC-10A (ALWKKLLKK-Cha-NH2),
by balancing the net charge and hydrophobicity. Additionally, cyclohexanylalanine (Cha) was
introduced at the C-terminus to improve the membrane permeabilization [13]. Although DMPC-10A
has demonstrated broad-spectrum inhibitory activity, it still induces a considerable hemolytic effect [13].
D-amino acids are enantiomeric residues that are occasionally found in the constitutions of natural
proteins. The peptide bond formed by D-amino acids is resistant to enzymatic hydrolysis. On the other
hand, the substitution of D-enantiomer in AMPs has demonstrated a change in secondary structure that
decreases the cytotoxicity to zwitterionic cell membranes and improves stability [14–17]. In previous
studies, researchers have substituted all of the amino acids in naturally occurring membrane-active
peptides such as cecropin A, magainin 2 amide, and melittin with D-type amino acids, and these
enantiomers were demonstrated to be resistant to enzymatic degradation, showing activity similar
to that of their natural form [18–20]. However, an enantiomer may not be suitable as a therapeutic
agent because its extremely long half-life may increase the side effects. An alternative method
by which to overcome this limitation is to design partial D-amino acid substitution analogues of
natural peptides [15]. Some studies have pointed out that D-type leucine and lysine substitution
can significantly improve the stability of peptides against trypsin degradation and have exhibited
more efficient killing of Gram-negative and Gram-positive bacteria [16,21]. In this study, we designed
an analogue of DMPC-10A with substitutions of L-Lys and L-Leu by respective enantiomeric D-amino
acid residues and further assessed antimicrobial activity using the Galleria mellonella larva model.
2. Results
2.1. Structure Analysis of DMPC-10B
The epimerization of the D-amino acid close to the N-terminus has been determined to have
an impact on the average helicity of a peptide, which is an important parameter for the antimicrobial
activity and selectivity of AMPs [22]. Unlike DMPC-10A, which could form an obvious α-helix
structure in an amphipathic environment, DMPC-10B has demonstrated a left-handed α-helix structure
in trifluoroethanol (TFE) (Figure 1). Based on the helical secondary structures, molecular modeling
was performed to show the conformation of both peptides (Figure 2).
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Figure 1. Secondary structure analysis of DMPC-10A and DMPC-10B; 50-µM peptides analyzed by
treatment with 10 mM NH4AC and 50% trifluoroethanol (TFE)/10 mM NH4AC. The spectra were
averaged over three consecutive scans and the solvent circular dichroism (CD) signal was subtracted.
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2.2. Antimicrobial Activities
DMPC-10A and DMPC-10B were able to inhibit the growth of the bacteria strains in this study.
The cell viability of each bacterium treated by the respective peptide is showed in Figure S1. DMPC-10B
demonstrated broad-spectrum inhibitory activity, where its minimum in ibitory concentrations were
around 2 to 64 µM (Table 1). Compared with DMPC-10A, the antibacterial performance f DMPC-10B
for E. coli a methicillin-resistant Staphylococcus aureus ( RSA) was improved four-fold and two-fold,
respectively, while for K. pneumoniae (ATCC 43816), the MIC showed a two-fold increase. Generally,
two peptides exhibit similar antimicrobial otency.
Table 1. The minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs)
of DMPC-10A and DMPC-10B against selected microorga isms. MICs of antibiotics (ge tam cin,
vancomycin and norfloxaci ) were tested as well.
Strains
MICs/MBCs (µM) MICs (µg/mL)/(µM)
DMPC-10B DMPC-10A Gentamicin Vancomycin Norfloxacin
Gram-positive
bacteria
S. aureus
(NCTC 10788) 4/16 4/8 <0.0625/<0.13 0.125/0.08 2/6.26
MRSA
(NCTC 12493) 4/8 8/16 0.125/0.26 0.125/0.08 2/6.26
E. faecalis
(NCTC 12697) 64/64 64/64 4/8.38 / . / .
Gram-negative
bact ria
E. coli
(NCTC 10418) 2/4 8/8 1/2.09 > / . / .
K. pneumoniae
(ATCC 43816) 8/8 4/64 1/2.09 >32/>22.07 2/6.26
K. pneumoniae
(ATCC BAA 1705) 32/32 32/32 2/4.19 > / . > / .
K. pneumoniae
(ATCC BAA 2342) 16/16 16/16 4/8.38 >32/>22.07 >32/>100.21
P. aeruginosa
(ATCC 27853) 4/32 4/4 0.25/0.52 >32/>22.07 2/6.26
Overall, the antimicrobial activity of DMPC-10A and DMPC-10B was proven to be affected
by the presence of different cations (Figure S2). Cations such as Mg2+ and Ca2+ showed a similar
influence on MICs at two concentrations (2 and 5 mM) (Table 2). However, compared with DMPC-10A,
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DMPC-10B is more sensitive to Na+ in the environment. Additionally, 10% of fetal bovine serum (FBS)
has less influence on the antimicrobial activity of two peptides than the cations.
Table 2. Effect of MgCl2, CaCl2, NaCl and fetal bovine serum (FBS) on the antimicrobial activity of
DMPC-10B against S. aureus (NCTC 10788) and E. coli (NCTC 10418).
Additive Concentration
MICs of DMPC-10B (µM) MICs of DMPC-10A (µM)
S. aureus E. coli S. aureus E. coli
None - 4 2 4 8
MgCl2
2 mM 32 16 32 32
5 mM 64 32 64 64
CaCl2
2 mM 32 16 32 32
5 mM 64 32 64 64
NaCl
150 mM 64 16 32 16
375 mM 128 32 64 32
FBS 10% 8 4 16 16
2.3. Enzyme Stability
Unlike the similar pattern of DMPC-10A and DMPC-10B in the medium containing cations or FBS,
they demonstrated different degrees of tolerance towards the hydrolysis by trypsin and chymotrypsin
(Figure 3). This revealed that trypsin completely cleaved DMPC-10A in 10 min with the appearance of
fragment peaks in the HPLC chromatogram traces (Figure S3), whereas it could not degrade DMPC-10B
completely within 2 h. Similarly, chymotrypsin cleaved DMPC-10A in 40 min, while DMPC-10B
exhibited resistance to the hydrolysis. This proves that the substitution of D-amino acids could
significantly improve the stability of DMPC-10B in the presence of endogenous enzymes.
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Figure 3. The amount of intact peptides of DMPC-10A and DMPC-10B undergoing in vitro hydrolysis
by trypsin and chymotrypsin in 120 min. The error bar represents the standard deviation (SD) of
three replicates.
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2.4. Hemolytic and Cytotoxic Activity
We evaluated the cytotoxicity of DMPC-10A and DMPC-10B on the human keratinocyte cell
line, HaCat, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate
dehydrogenase (LDH) assays. DMPC-10B did not induce any cytotoxicity on HaCat at a concentration
up to 128 µM (Figure 4). Similarly, DMPC-10B did not exhibit any hemolytic activity on the horse
erythrocytes. However, compared with DMPC-10B, DMPC-10A induced more severe hemolysis
and cytotoxicity.
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Figure 4. The cytotoxicity evaluation of DMPC-10A (black) and DMPC-10B (grey). (a) The cell viability
of HaCat (human keratinocyte cell line) treated by DMPC-10A and DMPC-10B. (b) The release of lactate
dehydrogenase (LDH) from HaCat cells in the presence of DMPC-10A and DMPC-10B. (c) The hemolytic
activities of DMPC-10B and DMPC-10A at concentrations of 1 to 512 µM. The percentage was calculated
based on the effect induced by a positive control, 1% Triton X-100. Treatment with phosphate-buffered
salin (PBS) used as a neg tive control. Error bars indicate standard deviation (SD) of 15 replicates
in three tests (5 replicates each tim ). The statistical significance was c lculated using one-way ANOVA
and is indicated as ns (nonsignificant diff rence), * (p < 0.05), ** (p < 0.01), and **** (p < 0.0001).
2.5. Membrane Permeability
As the results show (Figure 5), both DMPC-10A and DMPC-10B permeabilize the cell membrane
of S. aureus and K. pneumoniae. As we know, phosphatidylcholine (PC) is predominant in the outer
leaflet of the plasma membrane of mammalian cells [23]. Considering that DMPC-10B exerted low
cytotoxicity and hemolytic activity on mammalian cells, 1 mg/mL of dipalmitoylphosphatidylcholine
(DPPC) small unilamellar vesicle (SUVs) was added to further explore the selectivity of the peptides
to the lipid layer with different lipid constitutions. It showed that DPPC SUVs interfered with
the interaction between DMPC-10A and the bacterial cell membrane, decreasing the membrane
permeabilization effect on S. aureus and K. pneumoniae. Ho ever, the membrane permeabilization of
DMPC-10B was not affected significantly by the presence of DPPC SUVs. Furthermore, the docking
analysis of both peptides in the 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE)
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid bilayers showed that DMPC-10B
revealed a slightly higher binding affinity to the POPE lipid bilayer (Figure S4).
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Figure 5. Kinetics of membrane permeabilization of DMPC-10A and DMPC-10B on S. aureus (NCTC
10788) and K. pneumoniae (ATCC 43816) at 16 µM. To determine the lipid selectivity of both peptides,
1 mg/mL of dipalmitoylphosphatidylcholine (DPPC) small unilamellar vesicle (SUVs) was added.
The percentage of membrane permeabilization was measured using the bacterial cells treated with 70%
isopropanol. The error bar represents the standard deviation (SD) of five replicates.
2.6. Antibiofilm Activities
S. aureus (NCTC 10788), MRSA (NCTC 12493) and K. pneumoniae (ATCC 43816) were selected
for studying the anti-biofilm activity of DMPC-10A and DMPC-10B, due to their low MICs against
the respective strains. As shown in Figure 6, DMPC-10A and DMPC-10B effectively inhibited
the formation of biofilms of S. aureus and MRSA, but the effect is less potent against K. pneumoniae.
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Especially, they exhibited a relatively stronger effect on S. aureus. Meanwhile, both peptides displayed
around 50% biofilm eradication effect at the high concentrations ranging from 32 to 128 µM against
S. aureus and MRSA, while they showed more potent effects against K. pneumoniae at 64 µM and 128 µM
(Figure 6). Overall, DMPC-10B exerted a similar effect to DMPC-10A, except that it demonstrated
slightly effective activity to eradicate the biofilm of MRSA.
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Figure 6. The percentage of biofilm mass of S. aureus (NCTC 10788), MRSA (NCTC 12493),
and K. pneumoniae (ATCC 43816) after treatment with DMPC-10A and DMPC-10B in the biofilm
inhibition and eradication assays. The error bar represents the standard deviation (SD) of 15 replicates
in three tests (5 replicates each time). The statistical analysis was performed by one-way ANOVA
and the statistical significance between the peptide concentrations and the negative control (medium
treatment) is indicated as ns (nonsignificant difference), * (p < 0.05), ** (p < 0.01), *** (p < 0.001)
and **** (p < 0.0001).
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2.7. Antimicrobial Synergy Study
Previous research has confirmed that many AMPs are able to lyse the biological membrane
and generate pores by different mechanisms, such as toroidal pore and barrel stave models, which
could consequently allow the antibiotics to bypass the bacterial cell membrane in large numbers and kill
the bacteria [24,25], thereby achieving a synergistic effect. The principle is the same as the clinical
application of the combination of the membrane-rupturing antibiotics and the intracellular-targeting
antibiotics. Gentamicin can bind to 30S rRNA to inhibit the protein synthesis of bacteria [26,27].
The kinetics of uptake of gentamicin involve an initial energy-independent phase associated with ionic
binding to the cell surface and cytoplasmic membrane. This is followed by two energy-dependent
phases, a slow initial rate of uptake termed energy-dependent phase I (EDP-I) and a second accelerated
rate termed energy-dependent phase II (EDP-II) [28]. Although gentamicin demonstrates poor cell
permeability, it was reported that the combination of gentamicin and the highly cationic and amphipathic
α-helical peptide PMAP-36 or PRW4 could enhance the antimicrobial effect and exert a synergistic
effect, which may result from the easier access to the cytoplasmic membrane for gentamicin after
the disruption of the outer membrane by the two peptides [29,30]. Therefore, we speculated that
DMPC-10B, with the ability to rupture and penetrate the cell membrane, could help the uptake of
gentamicin and achieve a synergistic effect.
K. pneumoniae (ATCC BAA 1705) and K. pneumoniae (ATCC BAA 2342), two kinds of KPC-producing
K. pneumoniae strains, show resistance to cephamycins and carbapenems in addition to the substrate
range of extended-spectrum β lactamases (ESBLs) [31,32]. Actually, a nosocomial outbreak caused by
gentamicin-resistant Klebsiella pneumoniae occurred in the Neonatal Intensive Care Unit (NICU) [33].
Therefore, there is an urgent need for improving the therapeutic approaches against multidrug-resistant
bacteria; to achieve this, the synergistic application of AMPs and conventional antibiotics would be
a promising strategy.
The synergistic effects between DMPC-10B and gentamicin or norfloxacin were studied using
a checkerboard assay (Figure S5). The combination of DMPC-10B and gentamicin shows a synergistic
effect on K. pneumoniae (ATCC 43816), K. pneumoniae (ATCC BAA 1705), and K. pneumoniae (ATCC
BAA 2342). The lowest fractional inhibitory concentration index (FICI), which is used to measure
the combined effect of different compounds, was 0.375 for three bacteria (Table 3). In the meantime,
DMPC-10B showed only an addictive effect in the combination with norfloxacin.
Table 3. Synergistic effect of DMPC-10B with gentamicin and norfloxacin against the growth of
K. pneumoniae (ATCC 43816), K. pneumoniae (ATCC BAA 1705), and K. pneumoniae (ATCC BAA 2342).
The MICs are shown as the combined MIC/individual MIC. The fractional inhibitory concentration
index (FICI) was calculated and interpreted as synergistic for FICI ≤ 0.5, additive for 0.5 < FICI ≤ 4.0,
and antagonistic for FICI > 4.0.
Combination
Bacteria Strains
K. pneumoniae (ATCC 43816) K. pneumoniae (ATCC BAA 1705) K. pneumoniae (ATCC BAA 2342)
DMPC-10B 1/8 4/32 2/16
Gentamicin 0.25/1 0.5/2 1/4
FICI
(DMPC-10B/Gentamicin) 0.375 0.375 0.375
DMPC-10B 4/8 32/32 16/16
Norfloxacin 0.125/1 0.0625/>32 0.0625/>2
FICI
(DMPC-10B/Norfloxacin) 0.625 >1 >1
2.8. Treatment of Larvae Infected with MRSA and K. pneumoniae with DMPC-10B
The mortality of the larvae infected by MRSA and K. pneumoniae was significantly decreased by
the treatment of DMPC-10B (Figure 7). In addition, the highest dose of DMPC-10B did not induce any
death of healthy larvae. DMPC-10B significantly improved the mortality of infected larvae. It exhibited
a stronger effect on larvae infected with K. pneumoniae at a higher concentration (20 mg/kg), with
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around 70% survival, while only 50% larvae infected by MRSA survived at the same dose of DMPC-10
in 5 days. In contrast, the effects of the lower doses (5 mg/kg and 10 mg/kg) are similar in treatment of
the infections by MRSA and K. pneumoniae.
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Figure 7. The mortality of Galleria mellonella larvae infected with (a) methicillin-resistant Staphylococcus
aureus (MRSA) (NCTC 12493) and (b) K. pneumoniae (ATCC 43816). The infected larvae were treated
with gentamicin (20 mg/kg), PBS, and different doses of DMPC-10B, respectively. The larvae without
infection were treated with 20 mg/kg of DMPC-10B, which was applied to assess the potential toxicity
of DMPC-10B to the hosts. The statistical analyses were performed by log-rank test to compare with
the negative control (PBS treatment). The statistical significance is indicated as ns (nonsignificant
difference), * (p < 0.05), ** (p < 0.01), and *** (p < 0.001).
3. Discussion
AMPs, exerting remarkable antimicrobial effects, especially against multidrug-resistant bacterial
strains, have emerged as promising alternatives to antibiotics [34,35]. DMPC-10A is a potent N-terminal
derivate of der aseptin that has demonstrated broad-spectrum antimicrobial activity. The introduction
of a Cha residue at the C-terminus has enhanced the membrane permeabilization effect on the bacterial
cell membrane. Meanwhile, due to the strong hydrophobicity of the cyclohexyl group of Cha residue,
DMPC-10A also revealed considerable hemolytic activity. Additionally, that DMPC-10A consists of
L-amino acid contributes to the obstacle of poor stability in the presence of proteases, which limits
the clinical application [36]. As previous research pointed out, a feasible method to overcome these
limitations is to substitute the L-amino acids at the most susceptible site with D-amino acids [15].
Obviously, D-amino acid substitution does not change the net positive charge of the original peptide,
but the configuration and the action related to the recognition of chiral targets would be affected [16,37].
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Most AMPs kill bacteria by the destruction of the cell membrane through pore-forming activity [38,39].
Additionally, it is well established that the all-D enantiomers (the natural peptides consist of all
D-amino acids) with the left-handed α-helical structure are equally active and pore-forming [19,40].
Compared with the all-D enantiomers, the bioactivity of the analogues with partial substitution by
D-amino acid is more unpredictable. For some cases, such as the peptide W3R6, partial substitution
(D-Arg-W3R6) made it exert stronger antimicrobial activity than the all-D enantiomer (D-W3R6) [41].
However, for another AMP, polybia-CP, the partial D-lysine substitution derivative (D-Lys-CP) showed
slightly weaker antimicrobial activity than the all all-D enantiomer (D-CP) [42]. Herein, we replaced
the L-amino acids in the helical region of DMPC-10A with D-amino acids to produce a left-handed
α-helical structure in the membrane-mimicking environment (Figure 1) to retain the amphipathic
feature for the interaction with the lipid bilayer. Meanwhile, 1Ala and 3Trp still remained as L-form
because we aimed to reduce some helicity of the peptide, which might decrease the interaction with
the zwitterionic lipid that is commonly distributed in the mammalian cell membrane [8,13,43].
As the CD spectrum showed, DMPC-10B formed a left-handed α-helical structure, allowing it to
interact with the cell membrane. However, the helicity of DMPC-10B is lower than that of DMPC-10A,
which could be deduced from the reduced peak area at 208 and 222 nm. Additionally, the antimicrobial
activity of DMPC-10B was not severely affected by the substitution of the D-amino acids. Meanwhile,
the antimicrobial activity of DMPC-10B against E. coli was increased significantly. On the other hand,
both peptides were influenced by the cations in the environment, where the antimicrobial potency of
DMPC-10B was affected more severely than that of DMPC-10A. This may result from the competitive
binding of cations and cationic peptide on the cell membrane of bacteria [44]. However, the larger
helical segment of DMPC-10A could still facilitate binding with the lipid bilayer.
On the contrary, we found that phosphatidylcholine (PC) greatly affected the membrane
permeabilization of DMPC-10A, but it did not extensively impact the effect of DMPC-10B. This indicates
that DMPC-10B possesses selectivity towards the cell membrane with different lipid constitutions.
It is also consistent with the explanation of the different activities of DMPC-10A and DMPC-10B
towards the mammalian cell line and the erythrocytes. Again, we assume that DMPC-10A may
exert two ways for binding to the lipid bilayer, one is the electrostatic interaction and another is
the amphipathic interaction by the helical formation. Therefore, it could interact with the negatively
charged bacterial cell membrane as well as the zwitterionic lipid bilayer. However, due to the less
helical configuration of DMPC-10B, electrostatic interaction could be the predominant pattern in
the process of killing mechanism. It was deduced that DMPC-10B was less effective on HaCat cells
and red blood cells, as their outer leaflet of the plasma membrane contains predominant zwitterionic
PC [23]. However, the main lipid components of the bacterial cell membrane are negatively charged
phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) [45]. Besides this, the previous study
demonstrated that peptide substituted by D-amino acid could not deeply insert into the hydrophobic
core of the zwitterionic lipid bilayer [17].
In addition, DMPC-10B showed great stability in trypsin and chymotrypsin environment. In nature,
the majority of proteins and peptides consist of L-amino acids that can be hydrolyzed by endogenous
enzymes. However, D-amino acid associated peptide bonds could alter the direction of the side chain
and twist the backbone of the main chain, which prevents the binding to the enzyme [37]. Moreover,
the L-Trp in DMPC-10B, which can be cleaved by chymotrypsin, was not cleaved within 2 h. It is
speculated that Trp is connected with D-amino acids, where the spatial structure could be changed to
place into the rection pocket of the enzyme. This situation is similar to that of the presence of Pro at P1′
position, which can block hydrolysis by trypsin or chymotrypsin [46].
Notably, the growth of tested antibiotic strains in our study was effectively inhibited by DMPC-10B
individually as well as in combination with conventional antibiotics. As we know, AMPs are excellent
antimicrobial candidates which have been considered to be less subjected to the development of
resistance [47]. It has also been proven as a promising solution to amplify the potency of conventional
antibiotics through drug combination. For instance, the antimicrobial potency of amoxicillin has been
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enormously enhanced in the combined use of clavulanic acid [48]. Herein, DMPC-10B displayed
synergistic activities with gentamicin against K. pneumoniae. The mechanism of action of gentamicin
involves creating fissures in the outer membrane of the bacterial cell and inhibition of bacterial protein
synthesis by binding to 30S ribosomes [49,50]. The previous study showed that the combination of
gentamicin and highly cationic and amphipathic α-helical peptides would exert a synergistic effect,
as it could be the easier for gentamicin to traverse the cytoplasmic membrane after the permeabilization
of the outer membrane by the peptides [29,30]. Although the mechanism of the synergetic effect
between DMPC-10B and gentamicin remains unrevealed, DMPC-10B may possess direct and selective
membrane permeabilizing activity to facilitate the translocation of gentamicin into the bacterial cells
and initiate the process to bind with intracellular 30S ribosomes, which leads to the enhancement
of the antimicrobial activity [51]. The application of the combination of AMPs and conventional
antibiotics could be a prospective strategy to combat multidrug resistant pathogens and decrease
the side effect of antibiotics at high doses [52].
Wax moth (G. mellonella) larva infection model was used to assess the efficacy of DMPC-10B
against MRSA and K. pneumoniae in vivo. Compared with the other AMPs applied using the same
model, such as Japonicin-2LF [53], DMPC-10B exerted relatively stronger efficacy. Japonicin-2LF
prevented around 50% mortality at 50 mg/kg in treatment of MRSA infection, but DMPC-10B achieved
similar efficacy at 20 mg/kg. Additionally, Japonicin-2LF exhibited over 80% hemolysis and induced
considerable cytotoxicity [53]. The more potent antimicrobial efficacy of DMPC-10B might be related
to the resistance to enzymatic degradation, which might prolong the half-life in vivo. Collectively,
the design of DMPC-10B not only reduces the hemolysis and cytotoxicity but also contributes to
the enhancement of the antimicrobial efficacy. Although DMPC-10B did not exhibit improved efficacy
compared with gentamycin in vitro, it still exerted similar potency to gentamycin at the dose of
20 mg/kg against K. pneumoniae, suggesting that DMPC-10B has great potential for development
as an antibiotic alternative to combat the rising issue of antibiotic resistance.
4. Materials and Methods
4.1. Solid Phase Peptide Synthesis
Fmoc-chemistry peptide synthesis was performed for all peptides in this study, using a Tribute
Peptide Synthesiser (Protein Technologies, Tucson, AZ, USA), which was described in the previous
study [53]. Briefly, 0.3 mmol of each Fmoc amino acid was weighted and mixed with an equal amount
of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (hexafluorophosphate
benzotriazole tetramethyl uronium, HBTU) in the loading vial. Rink amide resin (250 mg) was
employed as the solid phase for the synthesis of peptide chain as well as providing the C-terminal
amide for all peptides. In the synthesis process, the peptide bonds were coupled in the presence of
HBTU that was dissolved by 1 M N-methylmorpholine (NMM) in dimethylformamide (DMF), followed
by the deprotection of α-NH2 by 20% (v/v) piperidine in DMF. Once the synthesis was accomplished,
a 25 mL cleavage cocktail (trifluoroacetic acid (TFA)/water/thioanisole/1,2-Ethanedithiol = 94/2/2/2
(v/v/v/v)) was added to the resin–peptide matrix for 2–4 h at room temperature for releasing the peptide
chains from the resin as well as deblocking the side chains. The synthetic peptides were purified by
reverse-phase HPLC and lyophilized for functional tests.
4.2. Molecular Modeling and Docking
Molecular modeling was employed using UCSF Chimera software package [54]. The two
peptides were built, and the conformations were adjusted with the minimization simulation, using
the non-solvation environment. The coulombic surface was presented to show the positive charge of
the side chains. For molecular docking, AutoDock vina [55] was employed to simulate the interaction
between the energy adjusted peptides and different lipid bilayers. The POPE and POPC lipid bilayer
models were provided by Tieleman [56].
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4.3. Circular Dichroism (CD)
The secondary structure of all synthetic peptides was investigated using a JASCO J-815 CD
Spectropolarimeter (JASCO Inc., Tokyo, Japan) as described in the previous study [57]. Each peptide
was prepared in 10 mM ammonium acetate (NH4AC; Sigma-Aldrich, Gillingham, UK) buffer (pH 7.4)
and the membrane-mimic solution 50/50 (v/v) 2,2,2-trifluoroethanol (TFE; Sigma-Aldrich, Gillingham,
UK)/10 mM NH4AC (pH 7.4), at a final concentration of 50 µM, respectively. The solution was loaded
in a 1-mm thickness quartz cuvette and analyzed at room temperature. The range of the wavelength for
analysis was programmed from 190 to 250 nm. The peptide sample was scanned by a 1 nm bandwidth
light at 0.5 nm data pitch at the speed of 100 nm/min. The final spectrum of each sample was generated
by averaging data from three scans.
4.4. Antimicrobial Assay
The antimicrobial activity of the peptides was generally assessed through the determination
of the minimum inhibitory concentrations (MICs) and the minimum bactericidal concentration
(MBCs) using the broth-dilution method, as described in the previous study [57]. Gram-positive
bacteria Staphylococcus aureus (NCTC 10788) and Enterococcus faecalis (NCTC 12697) and Gram-negative
bacteria Escherichia coli (NCTC 10418), Pseudomonas aeruginosa (ATCC 27853), and Klebsiella pneumoniae
(ATCC 43816) were tested. Additionally, the antibiotic-resistant strains, methicillin-resistant S. aureus
(MRSA, NCTC 12493), K. pneumoniae (ATCC BAA 1705), and K. pneumoniae (ATCC BAA 2342), were
also employed to investigate the potential application of all peptides against antibiotic resistance.
All the bacterial strains were inoculated in Mueller Hinton broth (MHB), pH 7.4 (Oxiod, Basingstoke, UK)
at 37 ◦C. Then, the log-phase bacteria were mixed with the peptide at the concentrations from 512 to
1 µM in two-fold dilution, in a 96 well-plate. The wells contained sterilized MHB and bacteria cultures
were employed as a blank and growth control, respectively. Besides this, gentamycin, vancomycin,
and norfloxacin were applied as positive controls.
Furthermore, the antimicrobial activity in the presence of MgCl2, CaCl2, NaCl and 10% fetal
bovine serum (FBS) was investigated. In detail, 2 and 5 mM of MgCl2 and CaCl2, and 150 and 375 mM
NaCl, were applied, respectively. The supplements were added into the medium that was used for
diluting the bacteria suspension. Then, the diluted bacteria culture was mixed with the peptide stock
solution in the 96-well plate, as mentioned above. The assay was performed three times and each assay
contained 5 replicates.
4.5. Enzyme Stability Assay
The peptides were dissolved in phosphate-buffered saline (PBS) and mixed with the respective
enzyme (trypsin and chymotrypsin) with a ratio of 100:1 (m/m). Then, 135 µl of the reaction solution
was transferred into a new vial. The hydrolysis reaction was immediately terminated by adding 15 µl
of 10% TFA at the different time points (0, 5, 10, 20, 40, 60, 120 min). The mixture was then analyzed
by reverse-phase HPLC and respective peak areas were calculated to obtain the residual amount of
peptides at different times.
4.6. Cytotoxicity Assay
The cytotoxicity assay was performed using Pierce™ LDH cytotoxicity assay kit (Thermo Fisher
Scientific, UK). The MTT assay was performed with a typical method as described in the previous
study [58]. Human keratinocyte cell line HaCat was treated with DMPC-10A and DMPC-10B
at concentrations from 128 to 1 µM and 1% Triton X-100 and PBS were set as a positive and a negative
control, respectively. For MTT assay, the formazan was dissolved by DMSO and detected at 540 nm
using the plate reader. The release of LDH was determined by Synergy HT plate reader (490 nm)
(Biolise BioTek EL808, Winooski, VT, USA) after a 6 h incubation at 37 ◦C. Moreover, 1% Triton X-100
and PBS were set as a positive and a negative control, respectively.
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4.7. Hemolysis Test
The hemolytic activity of each peptide was measured by incubating a range of peptide
concentrations from 512 to 1 µM in a two-fold dilution in a 2% suspension of the horse erythrocytes,
as described in a previous study [59]. Briefly, 200 µL of peptide solution of each concentration was
mixed with 200 µL of pre-washed erythrocyte suspension. Then, 5 µL of Triton X-100 was added
to 195 µL of PBS as a positive control and then mixed with 200 µL of the erythrocyte suspension.
The negative control was set as 200 µL of PBS mixed with 200 µL of the erythrocyte suspension. Then,
100 µl of the supernatant from each sample was transferred to a microtiter plate after 2 h incubation
and the absorbance was measured by a Synergy HT plate reader at 550 nm (BioTek, Minneapolis,
MN, USA).
4.8. Membrane Permeability Kinetic Assay
The permeability of the bacterial cell membrane was assessed by the uptake of a nucleic fluorescent
dye, SYTOXTM Green (Thermo Fisher Scientific, Waltham, MA, USA), which was described in a previous
study [58]. The bacteria were cultured to log phase and harvested by centrifugation at 1000 rcf for 20 min.
Followed by a wash step using 5% TSB/0.85% NaCl solution, the bacterial cells were resuspended
using the same solution and diluted to a OD value of 0.8 at 590 nm. The prepared bacterial culture
was subsequently mixed with the peptides and the dye in a black 96-well plate and then analyzed by
excitation and emission wavelengths of 485 and 528 nm at 37 ◦C for 120 min (interval 5 min), using
a Synergy HT plate reader (BioTek, Minneapolis, MN, USA).
Additionally, the dipalmitoylphosphatidylcholine (DPPC) small unilamellar vesicles (SUVs) were
prepared as described previously [60]. Then, 10 mg/mL DPPC dissolved in 1:1 (v/v) methanol/chloroform
was evaporated and hydrated in HEPES buffer to form the multilamellar vesicles (MLVs). Then,
the small unilamellar vesicles (SUVs) were achieved by sonication. The prepared DPPC SUVs were
added to the well to achieve a final concentration of 1 mg/mL.
The experiment contained 5 replicates. The 100% membrane permeabilization was achieved by
treatment with 70% isopropanol. The bacteria suspension mixed with SYTOX dye only was employed
as a negative control.
4.9. Antibiofilm Assays
The antibiofilm activity of synthetic peptides was evaluated via the inhibitory effect against
the formation of biofilm and the eradication of mature biofilm, which were performed as the previously
study [58] with minor modifications. With regard to the inhibition of biofilm formation, the peptides
were mixed with diluted bacteria culture in a 96-well plate and incubated at 37 ◦C for 24–48 h. Then,
the solution in each well was discarded. The biofilm was washed with PBS. Finally, the biofilm in each
well was stained by 100 µL of 0.1% crystal violet solution and further dissolved by 30% acetic acid.
The absorbance of dissolved crystal violet in each well was recorded at 595 nm. For the eradication of
mature biofilm, biofilm was formed with incubation at 37 ◦C for 24–48 h. Then, the plate was washed
with PBS and filled with the peptides which were prepared in the fresh medium. After treatment for
24 h at 37 ◦C, the plate was stained as mentioned above. Both assays were repeated three times, with 5
replicates each time.
4.10. Evaluation of Combination Effects of DMPC-10B
To evaluate the potential synergetic effect of DMPC-10B with the conventional antibiotics,
gentamycin and norfloxacin, against K. pneumoniae (ATCC 43816), K. pneumoniae (ATCC BAA 1705),
and K. pneumoniae (ATCC BAA 2342), a checkerboard assay was applied, as described previously [61,62].
The bacteria culture was prepared and diluted as performed in Section 4.4. Then, the bacteria dilution
was mixed with a different combination of DMPC-10B and the antibiotics in the 96-well plate. The wells
only contained individual peptides or antibiotics were applied as reference controls. Similarly,
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the turbidity of each well in the plate was measured at OD 550 nm, after incubation at 37 ◦C for 24 h.
The fractional inhibitory concentration index (FICI) of each combination was defined as follows:
FICI =
MIC of DMPC−10B in combination
MIC of DMPC−10B alone +
MIC of antibiotic in combination
MIC of antibiotic alone
The profile of the combination was interpreted as synergistic, additive, and antagonistic for FICI
≤ 0.5, 0.5 < FICI ≤ 4.0, and FICI > 4.0, respectively.
4.11. Assessing the Efficacy of DMPC-10B against MRSA and K. Pneumoniae Strains In Vivo
The assessment of in vivo antimicrobial activity of DMPC-10B was performed using the larva
of Galleria mellonella, as in the previous study, with minor modifications [63]. The infection model
was constructed by injecting 10 µL of MRSA (NCTC 12493) and K. pneumoniae (ATCC 43816) bacteria
suspension (5 × 107 CFU/mL) which was prepared in PBS. After 1 h, each infected larva was further
administered an injection of 10 µL of peptide solution at different doses of 5, 10, 20 mg/kg. The infected
larva that was administered 10 µL of PBS was employed as a negative control, while 20 mg/kg of
gentamicin was used as a positive control. Each group contained 10 larvae and all larvae were inspected
every 24 h for 5 days (the first day was 12 h).
5. Conclusions
As the major problem of antibiotic resistance worldwide has become serious, versatile
therapeutics and approaches have emerged for the development of antimicrobials. Herein, we
demonstrated a broad-spectrum and potent antimicrobial peptide, DMPC-10B, with negligible
hemolytic activity and cytotoxicity. It revealed a potent effect against wildtype bacteria strains
as well as the antibiotic-resistant bacteria in vitro. Additionally, it exhibited a high degree of resistance
to hydrolysis by trypsin and chymotrypsin, which could overcome the drawback for oral administration
of protein and peptide. Additionally, DMPC-10B exerted synergistic activity with gentamicin against
K. pneumoniae KPC strains, which might benefit clinical therapy in the treatment of multidrug-resistant
pathogens. Considering this remarkable feature, it is believed that DMPC-10B might be an optimized
AMP candidate, compared with the other naturally occurring AMPs with obvious cytotoxicity and low
bio-stability. Although, in this study, the larvae model may not reflect the real antimicrobial efficacy
of DMPC-10B in vivo, these results bring insights into the potential of the development of new
antibiotic alternatives.
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BAA 2342) (c,f). The error bar represents the standard deviation (SD) of 5 replicates.
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